Department of Biotechnology & Bioinformatics, School of Life Sciences, University of Hyderabad, Prof. C.R. Rao Road, Hyderabad 500046, India.
Department of Biotechnology & Bioinformatics, School of Life Sciences, University of Hyderabad, Prof. C.R. Rao Road, Hyderabad 500046, India.
Int J Biol Macromol. 2018 Aug;115:940-954. doi: 10.1016/j.ijbiomac.2018.04.090. Epub 2018 Apr 19.
Methionine aminopeptidase 2 (MAP2) is a principal regulator of apoptosis for Leishmania donovani and a potential candidate for the design and synthesis of novel antileishmanials. The LdMAP2 gene was cloned in pET28a(+)-SUMO vector, expressed in E. coli and then purified by chromatographic methods. It was found to be a monomer and required divalent metal ion for its activity against synthetic substrates with Co(II), Mg(II), Mn(II) and Ni(II) being the major activators. Moreover, Ca(II) showed the tightest binding with K value of 124.7 ± 9.2 μM, while Co(II) proved most efficient for catalysis with k value of 128.1 ± 4 min. The naturally occurring aminopeptidase B inhibitor bestatin was found to be a potent inhibitor of LdMAP2 with a K value of 0.86 μM. Further, structural studies with circular dichroism (CD) showed an increase in the α-helical and β-sheet contents and a decrease in random coils in LdMAP2 upon interactions with both bestatin and fluorogenic substrates. Finally, structural studies pointed out key differences in the structure of LdMAP2 and HsMAP2 and their interactions with inhibitor bestatin, Ala-AMC, Leu-AMC and Met-AMC. The structural differences of two orthologs and different binding modes with bestatin can be crucial for the development of novel and specific inhibitor against leishmaniasis.
蛋氨酸氨肽酶 2(MAP2)是利什曼原虫凋亡的主要调节因子,也是设计和合成新型抗利什曼原虫药物的潜在候选药物。LdMAP2 基因被克隆到 pET28a(+) - SUMO 载体中,在大肠杆菌中表达,然后通过色谱方法进行纯化。结果表明,它是一种单体,需要二价金属离子才能对合成底物发挥活性,其中 Co(II)、Mg(II)、Mn(II)和 Ni(II)是主要的激活剂。此外,Ca(II)与 K 值为 124.7±9.2μM 的结合最紧密,而 Co(II)在催化方面最为有效,k 值为 128.1±4min。天然存在的氨肽酶 B 抑制剂贝斯特atin 被发现是 LdMAP2 的有效抑制剂,K 值为 0.86μM。此外,圆二色性(CD)结构研究表明,在与贝斯特atin 和荧光底物相互作用时,LdMAP2 的α-螺旋和β-折叠含量增加,无规卷曲减少。最后,结构研究指出 LdMAP2 和 HsMAP2 的结构存在关键差异,以及它们与抑制剂贝斯特atin、Ala-AMC、Leu-AMC 和 Met-AMC 的结合模式不同。两种同源物的结构差异以及与贝斯特atin 的不同结合模式可能对开发新型、特异性抗利什曼病药物至关重要。